<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-title>BMC Infectious Diseases</journal-title><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15500691</article-id><article-id pub-id-type="pmc">PMC529257</article-id><article-id pub-id-type="publisher-id">1471-2334-4-44</article-id><article-id pub-id-type="doi">10.1186/1471-2334-4-44</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Adjuvant interferon gamma in patients with drug &#x02013; resistant pulmonary tuberculosis: a pilot study</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Su&#x000e1;rez-M&#x000e9;ndez</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmhbjuridico@infomed.sld.cu</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>Idrian</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>idrian.garcia@cigb.edu.cu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Fern&#x000e1;ndez-Olivera</surname><given-names>Norma</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmahjuridico@infomed.sld.cu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Vald&#x000e9;s-Quintana</surname><given-names>Magalys</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmahjuridico@infomed.sld.cu</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Milan&#x000e9;s-Virelles</surname><given-names>Mar&#x000ed;a T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmahjuridico@infomed.sld.cu</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Carbonell</surname><given-names>Dalia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmahjuridico@infomed.sld.cu</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Machado-Molina</surname><given-names>Delfina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>farmahjuridico@infomed.sld.cu</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Valenzuela-Silva</surname><given-names>Carmen M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carmen.valenzuela@cigb.edu.cu</email></contrib><contrib id="A9" contrib-type="author"><name><surname>L&#x000f3;pez-Saura</surname><given-names>Pedro A</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lopez.saura@cigb.edu.cu</email></contrib></contrib-group><aff id="I1"><label>1</label>"Ben&#x000e9;fico Jur&#x000ed;dico" Hospital, Havana, Cuba</aff><aff id="I2"><label>2</label>Center for Biological Research, Clinical Trials Division, Havana, Cuba</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2004</year></pub-date><volume>4</volume><fpage>44</fpage><lpage>44</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/4/44"/><history><date date-type="received"><day>27</day><month>2</month><year>2004</year></date><date date-type="accepted"><day>22</day><month>10</month><year>2004</year></date></history><copyright-statement>Copyright &#x000a9; 2004 Su&#x000e1;rez-M&#x000e9;ndez et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>Tuberculosis (TB) is increasing in the world and drug-resistant (DR) disease beckons new treatments.</p></sec><sec sec-type="methods"><title>Methods</title><p>To evaluate the action of interferon (IFN) gamma as immunoadjuvant to chemotherapy on pulmonary DR-TB patients, a pilot, open label clinical trial was carried out in the Cuban reference ward for the management of this disease. The eight subjects existing in the country at the moment received, as in-patients, 1 &#x000d7; 10<sup>6 </sup>IU of recombinant human IFN gamma intramuscularly, daily for one month and then three times per week up to 6 months as adjuvant to the indicated chemotherapy, according to their antibiograms and WHO guidelines. Sputum samples collection for direct smear observation and culture as well as routine clinical and thorax radiography assessments were done monthly.</p></sec><sec><title>Results</title><p>Sputum smears and cultures became negative for acid-fast-bacilli before three months of treatment in all patients. Lesion size was reduced at the end of 6 months treatment; the lesions disappeared in one case. Clinical improvement was also evident; body mass index increased in general. Interferon gamma was well tolerated. Few adverse events were registered, mostly mild; fever and arthralgias prevailed.</p></sec><sec><title>Conclusions</title><p>These data suggest that IFN gamma is useful and well tolerated as adjunctive therapy in patients with DR-TB. Further controlled clinical trials are encouraged.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Tuberculosis (TB) is not yet a defeated affection. Although controllable at a community level and curable in individuals, its eradication seems distant. At present, at least one third of the World's population, more than 1 500 million individuals are infected with the <italic>Mycobacterium tuberculosis. </italic>Every year, around 8 &#x02013; 10 million new cases occur [<xref ref-type="bibr" rid="B1">1</xref>]. Two million people die annually due to non-AIDS related TB, which is the highest number of deaths attributable to a single infectious agent [<xref ref-type="bibr" rid="B2">2</xref>], and corresponds to the 7<sup>th </sup>cause of death worldwide [<xref ref-type="bibr" rid="B3">3</xref>]. TB represents 26 % of avoidable deaths in developing countries [<xref ref-type="bibr" rid="B4">4</xref>]. The emergency of drug resistant (DR) or multidrug-resistant (MDR) strains has increased this global problem, leading to a high morbidity and mortality [<xref ref-type="bibr" rid="B5">5</xref>]. MDR-TB affected patients' mean survival ranges from 2 to 14 months [<xref ref-type="bibr" rid="B6">6</xref>]. According to the World Health Organization's (WHO) data, MDR patients global proportion is 2.2 % [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The infection is mainly transmitted by inhalation of the bacilli coming from respiratory airways infected secretions. Once inhaled, the bacilli are subjected to phagocytosis within the alveolar macrophages, where they can be destroyed. Nevertheless, <italic>Mycobacteria </italic>have developed mechanisms to adapt to the noxious intracellular environment. Thus, it can persist, replicate and disseminate, leading to new infectious foci. Resistance emergence depends on several factors such as initial bacillary load, inadequate or incomplete chemotherapy administration, and the patient's immune condition.</p><p>Chemotherapy is successful in most cases, given that the treatment schedule is thoroughly followed. It is prolonged, costly, and needs to be directly observed. Otherwise it is inadequate to kill all the bacilli and drug resistance emerges. Toxicities are frequent as well [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The immunologic approach to TB treatment can be promising since only 10 &#x02013; 20% of infected people develop the disease and many of them have spontaneous remission [<xref ref-type="bibr" rid="B9">9</xref>]. Interferon (IFN) gamma plays a main role in the immunity to TB. It is a glycoprotein, secreted by CD4+, CD8+ and NK cells. Nevertheless, CD4+ Th1 lymphocytes are the main producers in response to a stimulus [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Enough evidences exist related to IFN gamma action on the macrophages immunoregulatory activity [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>]]. Lack of production of this cytokine [<xref ref-type="bibr" rid="B15">15</xref>] or expression of its receptor [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] is associated to the infection's most lethal forms. Interferon gamma has also a potent antifibrotic effect [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Therefore a pilot clinical study was done with the aim to evaluate IFN gamma effect on drug resistant pulmonary TB patients regarding their clinical, bacteriological and radiological evolutions. The results show that the use of this protein in eight DR-TB patients (four of them MDR) as adjuvant to antibiotics had short and middle-term beneficial effects.</p></sec><sec sec-type="methods"><title>Methods</title><p>An open-label, non-randomized, non-controlled, pilot trial was carried out at the "Ben&#x000e9;fico -Jur&#x000ed;dico" Hospital, Havana, which is the national reference unit for TB and other respiratory diseases. According to the national TB program, all patients with unfavorable response to treatment are remitted to this center.</p><p>The study population was constituted by eight Cuban patients, both sexes, more than eighteen years old, with diagnosis of TB without a favorable response to the usual therapy, who gave their written, informed consent to participate. The diagnosis comprised clinical findings such as cough and expectoration, pulmonary lesions at thorax radiography, and positive DR-TB sputum-smear and culture. To confirm drug resistance the Canetti's multiple proportions method [<xref ref-type="bibr" rid="B21">21</xref>] was used as antibiogram. Exclusion criteria were another chronic disease, pregnancy or nursing, severe psychiatric dysfunction, multiple sclerosis or another autoimmune disorder, other pulmonary infections, HIV co-infection, and treatment with glucocorticoids or any other immunosuppressor medication.</p><p>The previous drug therapy received by the patients included 4 drugs (isoniazid, rifampin, streptomycin, and pyrazinamide) daily during 2 months, then isoniazid and rifampin twice per week for 2 additional months. Since their sputum tests had not become negative at this point they were returned to the 4 drugs regime plus ethambutol daily for 3 months, and finally isoniazid, rifampin, and ethambutol three times per week for 5 months.</p><p>The trial was done in compliance with the Helsinki Declaration. The protocol was approved by the hospital's Ethics Committee and by the Cuban Regulatory Authority. Data from nineteen historical control cases were obtained from the hospital's archives.</p><p>Patients received 1 000 000 IU of human recombinant IFN gamma (Heberon Gamma R<sup>&#x000ae;</sup>, Heber Biotec, Havana), intramuscularly, daily during 4 weeks and then 3 times per week for the next 20 weeks. Participants stayed as in-patients during the study period. They received anti-TB drugs (WHO schemes) [<xref ref-type="bibr" rid="B22">22</xref>], according to the resistance detected in each case by the antibiogram (Table <xref ref-type="table" rid="T1">1</xref>). Drugs were given as follows: rifampin 10 mg/Kg (maximum 600 mg), ethambutol 20 mg/Kg (max. 1500 mg), ethionamide 10 mg/Kg (max. 750 mg), pyrazinamide 15&#x02013;30 mg/Kg (max. 2000 mg), ciprofloxacin 15&#x02013;20 mg/Kg (max. 1500 mg), amikacin 15 mg/Kg (max. 1000 mg), and kanamycin 15 mg/Kg (max. 1000 mg) daily. After the end of the 6-months IFN gamma treatment period, chemotherapy continued up to 9 months if the scheme included rifampin and 18 months otherwise.</p><p>Evaluations were carried out at entry and monthly during IFN gamma treatment. A complete physical examination was done. Sputum samples were taken for acid-fast-bacilli smear and culture, as well as blood samples for hematological counts, globular sedimentation rate, alanine aminotransferase, and creatinin determinations. Thorax radiographies were also recorded. Afterwards, patients were followed up with half-yearly evaluations during one year.</p><p>Treatment efficacy evaluation included clinical, bacteriological and radiological outcomes. Complete response was defined as total disappearance of all signs and symptoms, negative sputum acid-fast-bacilli smear and culture, and pulmonary lesions improvement at X-ray. Partial response included signs and symptoms decrease, negative sputum smear and culture and stable X-ray lesions. No response consisted in signs and symptoms persistence, positive bacteriological examinations, and lesions stabilization or progression. Safety and tolerability of the IFN gamma treatment were monitored by means of a rigorous control of the adverse events that could be presented.</p></sec><sec><title>Results</title><p>Eight patients were enrolled in the study. Those were all the pulmonary DR-TB cases in the country during the inclusion period, from December 1999 to February 2002. They had not responded to the usual Directly Observed Treatment Short-course (DOTS) chemotherapy regime. Strain resistance was acquired in all cases. This was well determined since in Cuba all detected cases are screened for resistance on their first isolate. The patients did not have any extra-pulmonary manifestation of the disease. Their demographic and baseline characteristics are shown in Table <xref ref-type="table" rid="T1">1</xref>. Five of them were men, six of them non-white. The age ranged between 23 and 54 years old, and body mass index (BMI) between 13.2 and 22.0 Kg/m<sup>2</sup>. Their main symptoms were cough, expectorations, dyspnea, stertors, distal cyanosis, and finger clubbing. Bacteriological tests codification was mostly high and all patients showed active lesions at thorax radiography. Most of them had accelerated globular sedimentation rates (GSR). Anemia or other hematological alterations were not recorded.</p><p>A rapid favorable evolution was obtained after treatment with IFN gamma (Table <xref ref-type="table" rid="T2">2</xref>). Clinical improvement was evident since the first month of treatment, when all signs and symptoms (except for finger clubbing) had disappeared in all patients and BMI increased in all but one of them. Sputum acid-fast-bacilli smears and cultures were negative since the 1 &#x02013; 3 months of treatment. The eight patients had radiological improvement, with lesions size reduction (total disappearance in one case) (Figure <xref ref-type="fig" rid="F1">1</xref>). GSR decreased in five out of 6 patients who had abnormal values at inclusion. After six additional months follow-up, patients # 3 and 4 normalized it to 10 and 15 mm/h, respectively. At the end of the IFN gamma treatment all the patients were evaluated as complete responders.</p><p>The treatment with IFN gamma was safe and well tolerated. Four patients presented at least one adverse event. These events were arthralgias, fever, headache and asthenia. All adverse events were mild, except for one moderate fever, which was efficiently controlled with acetaminophen. Significant differences were not detected in other clinical laboratory tests.</p><p>After completion or the IFN gamma 6-months treatment the patients continued with the corresponding chemotherapy schedule. Seven of the eight patients remained bacteriologically, clinically and radiologically negative at least twelve months after the treatment with IFN gamma concluded. However, patient number five relapsed six months after the end of IFN therapy. He developed additional resistance to rifampin and ethionamide and a chronic obstructive respiratory disease that contributed negatively to his evolution.</p><p>Table <xref ref-type="table" rid="T3">3</xref> shows the results obtained at the same hospital with the 19 DR-TB cases during the five years prior to the present study. These patients had also failed to the standard DOTS regime. They were all resistant to isoniazid and rifampin, 13 were resistant to streptomycin, 7 to kanamycin, 4 to ethambutol, and one to pyrazinamide. Resistance was primary in 2 cases and acquired in the rest. Their average age was 58 years. Management was essentially the same as for the patients included in the study, except for IFN gamma treatment. None of these DR-TB cases reached culture conversion at three months of treatment with chemotherapy and less than half had converted at six months. Their clinical outcome was also worse.</p></sec><sec><title>Discussion</title><p>In spite of the reduced size of the population studied, the results suggest the efficacy of IFN gamma on DR-TB, when used as adjuvant to chemotherapy. All eight patients were considered as complete responders at the end of IFN treatment with disappearance of the disease signs and symptoms, sputum tests conversion, and pulmonary lesions improvement. Bacteriological and radiological improvement correlated with the clinical evolution; BMI increased and manifestations as cough and expectoration did not recur after IFN gamma treatment. Clinical practice demonstrates that these results are very difficult to obtain in such a short period of time with the chemotherapy alone.</p><p>Any conclusion from this study is also limited by the fact that it was not a controlled trial. This was not possible due to the low incidence of TB (7.6/100,000 inhabitants in 2002) [<xref ref-type="bibr" rid="B23">23</xref>] and DR-TB in Cuba [<xref ref-type="bibr" rid="B7">7</xref>]. Therefore a historical control with the results obtained at the same hospital by the same investigators in patients treated only with chemotherapy is used for comparison. Despite the fact that this kind of control is not fully comparable since they were not in the original design of the trial, a clear difference is shown regarding patients' performance. Literature reports on chemotherapy-treated DR-TB patients show similar unfavorable outcome [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The fact that four patients received rifampin, according to the strain sensitivity, which is one of the election drugs for the treatment of TB with excellent results in patients treated with DOTS regime, does not diminish the consideration regarding the possible benefit exerted by IFN gamma since these same patients had already not responded to this antibiotic as part of the DOTS. Moreover, one patient recurred after he had finished IFN gamma treatment for 6 months, despite still being under chemotherapy regime. This suggests that in his case a new IFN gamma cycle combined to the antibiotics would have been necessary, but this was not previewed in the protocol. However, only a controlled trial can definitely clarify the role of IFN gamma and second line antibiotics in this kind of patient's improvement.</p><p>The radiological results demonstrated IFN gamma antifibrotic properties as well. All patients had a reduction in the pulmonary lesions size, while one showed a complete resolution. This effect cannot be attributable to the antibiotics, since it is well known that DR-TB patients only develop radiological improvement long time after sputum smears and culture become negative. In many cases extensive fibrotic lesions never improve, and stay stable for life. This antifibrotic action agrees with that obtained with IFN gamma in idiopathic lung fibrosis [<xref ref-type="bibr" rid="B24">24</xref>] and suggests that IFN gamma can have future indications in other pulmonary diseases where fibrosis is present.</p><p>Therapy was well tolerated. It was not necessary to suspend the combined treatment due to adverse events; mostly mild. Adverse events such as arthralgias, fever and headache coincide with those reported for interferons [<xref ref-type="bibr" rid="B25">25</xref>].</p><p>Immunity to TB depends on the development of CD4+ cells- and macrophages-mediated Th1 response. The role of IFN gamma as the main macrophage-activator Th1 cytokine has been clearly established in animal models infected with <italic>M. tuberculosis </italic>[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. IFN gamma action on the macrophages leads to kill intracellular <italic>Mycobacteria</italic>. It stimulates macrophages to produce tumor necrosis factor alpha (TNF &#x003b1;), oxygen free radicals and nitric oxide, increase surface display of MHC antigens and Fc receptors, decrease lysosomal pH, and increase the intracellular concentration of some antibiotics [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B28">28</xref>].</p><p>Regarding its antifibrotic effect, IFN gamma inhibits lung fibroblast proliferation and chemotaxis in a dose dependent manner, and reduces collagen synthesis [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Furthermore, this protein is a potent inhibitor of the transforming growth factor &#x003b2; (TGF-&#x003b2;)[<xref ref-type="bibr" rid="B20">20</xref>], involved in the pathogenesis of many fibrotic lung diseases [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B32">32</xref>].</p><p>On the other hand, mutations in the IFN gamma gene [<xref ref-type="bibr" rid="B15">15</xref>], or in the IFN gamma receptor alpha chain gene [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>], increase susceptibility to develop the disease. Patients with disseminated BCG and other infections present defects in IFN gamma and other cytokines secretion and action [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>].</p><p>IFN gamma therapy has been shown effective for cerebral tuberculosis caused by a multidrug-resistant strain [<xref ref-type="bibr" rid="B36">36</xref>]. The aerosol route of administration has been proposed as organ specific delivery method, obtaining a high release to infected alveoli [<xref ref-type="bibr" rid="B37">37</xref>]. Condos et al. reported clinical and bacteriological improvement and tolerability with aerosolized IFN gamma in five patients with MDR-TB [<xref ref-type="bibr" rid="B38">38</xref>]. In addition, other previous trials demonstrated promising results in patients infected with other <italic>Mycobacteria </italic>[<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B39">39</xref>-<xref ref-type="bibr" rid="B42">42</xref>].</p></sec><sec><title>Conclusions</title><p>These results can suggest a beneficial effect of IFN gamma when it is used as adjuvant in the treatment of tuberculosis patients that have resistance to standard chemotherapy, and encourage carrying out more extensive, controlled studies. Combination with second-line drugs can reduce the time of treatment, diminishing toxicities and possible relapses; in many cases could reduce the application of recessional surgery. Further controlled clinical trials are needed to confirm these results.</p></sec><sec><title>Competing interests</title><p>Authors IGG, CMVS, and PALS are employees of the Center for Biological Research, which is part of the Center for Genetic Engineering and Biotechnology, Havana network, where IFN gamma is produced. The rest of the authors have no competing interests at all.</p></sec><sec><title>Authors' contributions</title><p>RSM conceived the study and carried out the bacteriological determinations. IGG participated in the study design and coordinating, and wrote the manuscript draft. NFO, MVQ, MTM, DC, and DMM took care of patient recruitment, management, and follow-up. CMVS participated in the study design and result analysis. PALS took part in the design, results analysis and manuscript writing. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/4/44/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgments</title><p>The authors wish to thank Dr. Carmen Rodr&#x000ed;guez and technician Helia Herrera for their participation in bacteriological testing. They also thank the technicians Nancy Silva, Leovaldo &#x000c1;lvarez and Yuselis Dom&#x000ed;nguez for their assistance. The authors received free drug (IFN gamma) from Heber Biotec, Havana, Cuba. The Ministry of Public Health of Cuba took care of hospital facilities and medical attention of the patients, including diagnostic procedures and the rest of the medicaments.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raviglione</surname><given-names>MC</given-names></name><name><surname>Snider</surname><given-names>DE</given-names></name><name><surname>Kochi</surname><given-names>A</given-names></name></person-group><article-title>Global epidemiology of tuberculosis: prevalence and mortality of a worldwide</article-title><source>JAMA</source><year>1995</year><volume>273</volume><fpage>220</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7807661</pub-id><pub-id pub-id-type="doi">10.1001/jama.273.3.220</pub-id></citation></ref><ref id="B2"><citation citation-type="other"><article-title>Tuberculosis</article-title><source>WHO information, Fact Sheet No 4</source><year>2000</year></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group><article-title>Mortality by cause for eight regions of the world: Global Burden of Disease Study</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1269</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9142060</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)07493-4</pub-id></citation></ref><ref id="B4"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Iseman</surname><given-names>MD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Goldman</surname></name></person-group><article-title>Tuberculosis</article-title><source>In Cecil Textbook of Medicine, Section Diseases due to Micobacteria</source><year>2000</year><edition>21</edition><fpage>1724</fpage><lpage>32</lpage></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellner</surname><given-names>JJ</given-names></name></person-group><article-title>Multidrug-resistant tuberculosis</article-title><source>Adv Intern Med</source><year>1995</year><volume>40</volume><fpage>155</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">7747646</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>AL</given-names></name><name><surname>Schluger</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Ron</surname><given-names>WN</given-names></name></person-group><article-title>Outcome of MDR-TB patients 1983&#x02013;1993: prolonged survival with appropriate therapy</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><fpage>317</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">8542137</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pablos-Mendez</surname><given-names>A</given-names></name><name><surname>Raviglione</surname><given-names>MC</given-names></name><name><surname>Laszlo</surname><given-names>A</given-names></name><name><surname>Binkin</surname><given-names>N</given-names></name><name><surname>Rieder</surname><given-names>HL</given-names></name><name><surname>Bustreo</surname><given-names>F</given-names></name><name><surname>Cohn</surname><given-names>DL</given-names></name><name><surname>Lambregts-van Weezenbeek</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Chaulet</surname><given-names>P</given-names></name><name><surname>Nunn</surname><given-names>P</given-names></name></person-group><article-title>Global surveillance for antituberculosis-drug resistance, 1994&#x02013;1997. World Health Organization &#x02013; International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1641</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9614254</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199806043382301</pub-id></citation></ref><ref id="B8"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Schluger</surname><given-names>NW</given-names></name><name><surname>Harkin</surname><given-names>TJ</given-names></name><name><surname>Rom</surname><given-names>WN</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rom, Garay</surname></name></person-group><article-title>Principles of therapy of tuberculosis in the modern era</article-title><source>Tuberculosis</source><year>1996</year><publisher-name>Little Brown, New York</publisher-name><fpage>751</fpage><lpage>9</lpage></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schraufnagel</surname><given-names>DE</given-names></name></person-group><article-title>Tuberculosis treatment for the beginning of the next century</article-title><source>Int J Tuberc Lung Dis</source><year>1999</year><volume>3</volume><fpage>651</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10460097</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galling</surname><given-names>JL</given-names></name><name><surname>Farber</surname><given-names>JM</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Nutman</surname><given-names>TB</given-names></name></person-group><article-title>Inteferon-&#x003b3; in the management of infectious diseases</article-title><source>Ann Intern Med</source><year>1995</year><volume>123</volume><fpage>216</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">7598304</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>SM</given-names></name></person-group><article-title>Therapy of mycobacterial infections</article-title><source>Res Immunol</source><year>1996</year><volume>147</volume><fpage>572</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9127890</pub-id><pub-id pub-id-type="doi">10.1016/S0923-2494(97)85224-8</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bermudez</surname><given-names>LE</given-names></name><name><surname>Inderlied</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>LS</given-names></name></person-group><article-title>Stimulation with cytokines enhances penetration of azithromicin into human macrophages</article-title><source>Antimicrob Agents Chemother</source><year>1991</year><volume>35</volume><fpage>2625</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1667256</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonecini-Almeida</surname><given-names>MG</given-names></name><name><surname>Chitale</surname><given-names>S</given-names></name><name><surname>Boutsikakis</surname><given-names>I</given-names></name><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Doo</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>JL</given-names></name></person-group><article-title>Induction of in vitro human macrophage anti-mycobacterium tuberculosis activity: Requirement for IFN&#x003b3; and primed lymphocytes</article-title><source>J Immunol</source><year>1998</year><volume>160</volume><fpage>4490</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9574555</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>HW</given-names></name></person-group><article-title>Interferon-&#x003b3; and host antimicrobial defense: current and future clinical applications</article-title><source>Am J Med</source><year>1994</year><volume>97</volume><fpage>459</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">7977435</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(94)90326-3</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name></person-group><article-title>Disseminated tuberculosis in interferon &#x003b3; gene-disrupted mice</article-title><source>J Exptl Med</source><year>1993</year><volume>178</volume><fpage>2243</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8245795</pub-id><pub-id pub-id-type="doi">10.1084/jem.178.6.2243</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Newport</surname><given-names>M</given-names></name></person-group><article-title>Unraveling the genetic basis of susceptibility to mycobacterial infection</article-title><source>J Pathol</source><year>1997</year><volume>181</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9071996</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199701)181:1&#x0003c;5::AID-PATH731&#x0003e;3.3.CO;2-O</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dormand</surname><given-names>SE</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name></person-group><article-title>Mutation in the signal-transducing chain of the interferon-&#x003b3; receptor and susceptibility to mycobacterial infections</article-title><source>J Clin Invest</source><year>1998</year><volume>101</volume><fpage>2364</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9616207</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sempowski</surname><given-names>GD</given-names></name><name><surname>Derdak</surname><given-names>S</given-names></name><name><surname>Phipps</surname><given-names>RP</given-names></name></person-group><article-title>Interleukin 4 and interferon gamma discordance regulate collagen biosynthesis by functionally distinct lung fibroblast subsets</article-title><source>J Cell Physiol</source><year>1996</year><volume>167</volume><fpage>290</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8613470</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrop</surname><given-names>AR</given-names></name><name><surname>Ghahary</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>PG</given-names></name><name><surname>Forsyth</surname><given-names>N</given-names></name><name><surname>Friedland</surname><given-names>A</given-names></name><name><surname>Tredget</surname><given-names>EE</given-names></name></person-group><article-title>Effect of &#x003b3; interferon on cell proliferation, collagen production and procollagen mRNA expression in hypertrophic scar fibroblast <italic>in vitro</italic></article-title><source>J Surg Res</source><year>1995</year><volume>58</volume><fpage>471</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7745958</pub-id><pub-id pub-id-type="doi">10.1006/jsre.1995.1074</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurujeyalakshmi</surname><given-names>G</given-names></name><name><surname>Giri</surname><given-names>SN</given-names></name></person-group><article-title>Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin model of lung fibrosis. Down regulation of TGF-beta and procollagen I and III gene expression</article-title><source>Exp Lung Res</source><year>1995</year><volume>21</volume><fpage>791</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">8556994</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Canetti</surname><given-names>G</given-names></name><name><surname>Rist</surname><given-names>N</given-names></name><name><surname>Grosset</surname><given-names>J</given-names></name></person-group><article-title>Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation</article-title><source>Rev Tuberc Pneumol (Paris)</source><year>1963</year><volume>27</volume><fpage>217</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">14018284</pub-id></citation></ref><ref id="B22"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Crofton</surname><given-names>J</given-names></name><name><surname>Chaulet</surname><given-names>P</given-names></name></person-group><article-title>Guidelines for the management of Drug-Resistant Tuberculosis</article-title><source>Word Health Organization</source><year>1997</year></citation></ref><ref id="B23"><citation citation-type="other"><person-group person-group-type="author"><collab>Ministry of Public Health of Cuba</collab></person-group><article-title>Anuario Estad&#x000ed;stico de Salud</article-title><year>2002</year><ext-link ext-link-type="uri" xlink:href="http://www.sld.cu/servicios/estadisticas.html"/></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziesche</surname><given-names>R</given-names></name><name><surname>Hofbauer</surname><given-names>E</given-names></name><name><surname>Wittmann</surname><given-names>K</given-names></name><name><surname>Petkov</surname><given-names>V</given-names></name><name><surname>Block</surname><given-names>LH</given-names></name></person-group><article-title>A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><fpage>1264</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10528036</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199910213411703</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vial</surname><given-names>T</given-names></name><name><surname>Descotes</surname><given-names>J</given-names></name></person-group><article-title>Clinical toxicity of the interferons</article-title><source>Drug safety</source><year>1994</year><volume>10</volume><fpage>115</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">7516663</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name></person-group><article-title>An essential role for interferon &#x003b3; in resistance to <italic>Mycobacterium tuberculosis </italic></article-title><source>J Exptl Med</source><year>1993</year><volume>178</volume><fpage>2249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">7504064</pub-id><pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Pitts-Meek</surname><given-names>S</given-names></name><name><surname>Keshav</surname><given-names>S</given-names></name><name><surname>Figari</surname><given-names>IS</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name></person-group><article-title>Multiple defects of immune cell function in mice with disrupted interferon-gamma genes</article-title><source>Science</source><year>1993</year><volume>259</volume><fpage>1739</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8456300</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PF</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Abrams</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Yamamura</surname><given-names>M</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name></person-group><article-title>Cytokine production at the site of disease in human tuberculosis</article-title><source>Infect Immun</source><year>1993</year><volume>61</volume><fpage>3482</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8335379</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienkowski</surname><given-names>RS</given-names></name><name><surname>Gotkin</surname><given-names>MG</given-names></name></person-group><article-title>Control of collagen deposition in mammalian lung</article-title><source>Proc Soc Exp Biol Med</source><year>1995</year><volume>209</volume><fpage>118</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7770462</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broekelmann</surname><given-names>TJ</given-names></name><name><surname>Limper</surname><given-names>AH</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>McDonald</surname><given-names>JA</given-names></name></person-group><article-title>Transforming growth factor beta is present at sites of extracellular matrix gene expression in human pulmonary fibrosis</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>6642</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1862087</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>N</given-names></name><name><surname>Whitman</surname><given-names>C</given-names></name><name><surname>Zuo</surname><given-names>L</given-names></name><name><surname>Danielpour</surname><given-names>D</given-names></name><name><surname>Greenberg</surname><given-names>A</given-names></name></person-group><article-title>Regulation of alveolar macrophage transforming growth factor beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat</article-title><source>J Clin Invest</source><year>1993</year><volume>92</volume><fpage>1812</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">7691887</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Limper</surname><given-names>AH</given-names></name><name><surname>Colby</surname><given-names>TV</given-names></name><name><surname>Asakura</surname><given-names>S</given-names></name><name><surname>Roche</surname><given-names>PC</given-names></name><name><surname>DeRemee</surname><given-names>RA</given-names></name></person-group><article-title>Immunohistochemical granulomas of pulmonary sarcoidosis</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">8111583</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Lamhamedi-Cherradi</surname><given-names>S</given-names></name><name><surname>Altare</surname><given-names>F</given-names></name><name><surname>Fondaneche</surname><given-names>MC</given-names></name><name><surname>Tuerlinckx</surname><given-names>D</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Gaillard</surname><given-names>JL</given-names></name><name><surname>Schreiber</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Hivroz</surname><given-names>C</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><article-title>Partial interferon-&#x003b3;-receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>2658</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">9389728</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Newport</surname><given-names>M</given-names></name></person-group><article-title>Understanding the genetic basis of susceptibility to mycobacterial infection</article-title><source>Proc Assoc Am Physicians</source><year>1999</year><volume>111</volume><fpage>308</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">10417738</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lammas</surname><given-names>DA</given-names></name><name><surname>Drysdale</surname><given-names>P</given-names></name><name><surname>Ben-Smith</surname><given-names>A</given-names></name><name><surname>Girdlestone</surname><given-names>J</given-names></name><name><surname>Edgar</surname><given-names>D</given-names></name><name><surname>Kumararatne</surname><given-names>DS</given-names></name></person-group><article-title>Diagnosis of defects in the type 1 cytokine pathway</article-title><source>Microbes and Infect</source><year>2000</year><volume>2</volume><fpage>1567</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">11113376</pub-id><pub-id pub-id-type="doi">10.1016/S1286-4579(00)01313-7</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raad</surname><given-names>I</given-names></name><name><surname>Hachem</surname><given-names>R</given-names></name><name><surname>Leeds</surname><given-names>N</given-names></name><name><surname>Sawaya</surname><given-names>R</given-names></name><name><surname>Salem</surname><given-names>Z</given-names></name><name><surname>Atweh</surname><given-names>S</given-names></name></person-group><article-title>Use of adjunctive treatment with interferon &#x003b3; in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain</article-title><source>Clin Infect Dis</source><year>1996</year><volume>22</volume><fpage>572</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8852983</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jaffe</surname><given-names>HA</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Mastrangeli</surname><given-names>A</given-names></name><name><surname>Holroyd</surname><given-names>KJ</given-names></name><name><surname>Saltini</surname><given-names>C</given-names></name><name><surname>Czerski</surname><given-names>D</given-names></name><name><surname>Jaffe</surname><given-names>HS</given-names></name><name><surname>Kramer</surname><given-names>S</given-names></name><name><surname>Sherwin</surname><given-names>S</given-names></name><name><surname>Crystal</surname><given-names>RG</given-names></name></person-group><article-title>Organ specific cytokine therapy: Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung</article-title><source>J Clin Invest</source><year>1991</year><volume>88</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">1905329</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Condos</surname><given-names>R</given-names></name><name><surname>Rom</surname><given-names>WN</given-names></name><name><surname>Schulger</surname><given-names>NW</given-names></name></person-group><article-title>Treatment of multidrug-resistant tuberculosis with interferon &#x003b3; via aerosol</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1513</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9167461</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(96)12273-X</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chatte</surname><given-names>G</given-names></name><name><surname>Panteix</surname><given-names>G</given-names></name><name><surname>Perrin-Fayolle</surname><given-names>M</given-names></name><name><surname>Pacheco</surname><given-names>Y</given-names></name></person-group><article-title>Aerosolized interferon gamma for <italic>Mycobacterium avium complex </italic>lung disease</article-title><source>Amer J Respir Crit Care Med</source><year>1995</year><volume>152</volume><fpage>1094</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7663788</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Eisenstein</surname><given-names>EM</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Turner</surname><given-names>ML</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Strober</surname><given-names>W</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name></person-group><article-title>Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><fpage>1348</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">7908719</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199405123301904</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Squires</surname><given-names>KE</given-names></name><name><surname>Brown</surname><given-names>ST</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>WF</given-names></name><name><surname>Murray</surname><given-names>HW</given-names></name></person-group><article-title>Interferon gamma treatment for <italic>Mycobacterium avium-intracellulare complex </italic>bacillemia in patients with AIDS</article-title><source>J Infect Dis</source><year>1992</year><volume>166</volume><fpage>686</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1500760</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>CF</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><name><surname>Levis</surname><given-names>WR</given-names></name><name><surname>Nusrat</surname><given-names>A</given-names></name><name><surname>Witmer</surname><given-names>MD</given-names></name><name><surname>Sherwin</surname><given-names>SA</given-names></name><name><surname>Job</surname><given-names>CK</given-names></name><name><surname>Horowitz</surname><given-names>CR</given-names></name><name><surname>Steinman</surname><given-names>RM</given-names></name><name><surname>Cohn</surname><given-names>ZA</given-names></name></person-group><article-title>Local and systemic effects of intradermal recombinant interferon-&#x003b3; in patients with lepromatous leprosy</article-title><source>N Engl J Med</source><year>1986</year><volume>315</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">3086725</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Radiological improvement with IFN gamma treatment (ray-x of two patients are shown). Patient 4 (A), left-lung fibroexudative lesions, and (B) complete resolution after IFN gamma treatment. Patient 2 (C), bilateral moderate exudative lesions before IFN gamma treatment, and (D) important improvement of the lesions afterwards.</p></caption><graphic xlink:href="1471-2334-4-44-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic and baseline characteristics of patients with DR-TB treated with IFN gamma</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Patient</bold></td><td align="center"><bold>1</bold></td><td align="center"><bold>2</bold></td><td align="center"><bold>3</bold></td><td align="center"><bold>4</bold></td><td align="center"><bold>5</bold></td><td align="center"><bold>6</bold></td><td align="center"><bold>7</bold></td><td align="center"><bold>8</bold></td></tr></thead><tbody><tr><td align="left"><bold>Age (years)</bold></td><td align="center">28</td><td align="center">50</td><td align="center">54</td><td align="center">27</td><td align="center">44</td><td align="center">50</td><td align="center">23</td><td align="center">37</td></tr><tr><td align="left"><bold>Sex</bold></td><td align="center">Male</td><td align="center">Male</td><td align="center">Female</td><td align="center">Female</td><td align="center">Male</td><td align="center">Male</td><td align="center">Female</td><td align="center">Male</td></tr><tr><td align="left"><bold>Race</bold></td><td align="center">Mestizo</td><td align="center">White</td><td align="center">Mestizo</td><td align="center">Mestizo</td><td align="center">White</td><td align="center">Mestizo</td><td align="center">Black</td><td align="center">Black</td></tr><tr><td align="left"><bold>BMI (Kg/m</bold><sup>2</sup><bold>)</bold></td><td align="center">19.6</td><td align="center">18.9</td><td align="center">13.2</td><td align="center">18.3</td><td align="center">14.6</td><td align="center">21.6</td><td align="center">22.0</td><td align="center">17.1</td></tr><tr><td align="left"><bold>Sputum smear status*</bold></td><td align="center">0</td><td align="center">9</td><td align="center">9</td><td align="center">9</td><td align="center">8</td><td align="center">9</td><td align="center">8</td><td align="center">9</td></tr><tr><td align="left"><bold>Sputum culture status**</bold></td><td align="center">7</td><td align="center">9</td><td align="center">7</td><td align="center">9</td><td align="center">6</td><td align="center">9</td><td align="center">8</td><td align="center">9</td></tr><tr><td align="left"><bold>Drug Resistance</bold></td><td align="center">INH<break/>RIF<break/>STR</td><td align="center">INH<break/>STR</td><td align="center">INH<break/>RIF<break/>STR</td><td align="center">INH<break/>RIF</td><td align="center">INH, STR</td><td align="center">INH<break/>RIF<break/>STR</td><td align="center">INH</td><td align="center">INH</td></tr><tr><td align="left"><bold>Initial thorax X-ray</bold></td><td align="center">R1</td><td align="center">R2</td><td align="center">R3</td><td align="center">R4</td><td align="center">R5</td><td align="center">R6</td><td align="center">R7</td><td align="center">R8</td></tr><tr><td align="left"><bold>GSR (mm/h)</bold></td><td align="center">5</td><td align="center">66</td><td align="center">53</td><td align="center">53</td><td align="center">68</td><td align="center">101</td><td align="center">10</td><td align="center">60</td></tr></tbody></table><table-wrap-foot><p>INH: Isoniazid; RIF: Rifampin; STR: Streptomycin; ETB: Ethambutol; ETN: Ethionamide; PRZ: Pyrazinamide; CPF: Ciprofloxacin; KAN: Kanamycin; AMK: Amikacin.</p><p>* Number of bacilli; 0: 0 in 4 lines; 8: 25 or more in 1 line; 9: bacilli in most of the fields.</p><p>** Number of colonies; 6: 6&#x02013;24 colonies; 7: 25&#x02013;100 colonies; 9: confluent growth.</p><p>R1 and R3. Extensive bilateral exudative lesions</p><p>R2: Moderate exudative lesions</p><p>R4: Left fibro-exudative lesions</p><p>R5: Moderate Bilateral fibro-exudative lesions.</p><p>R6: Cavitary lesions at superior lobes; fibrous lesions at right superior lobe; alveolar infiltrate at left superior lobe.</p><p>R7 and R8: Very diffuse fibromatous lesions at superior lobes.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Six months follow-up data of DR-TB patients treated with IFN gamma</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Patient</bold></td><td align="center"><bold>1</bold></td><td align="center"><bold>2</bold></td><td align="center"><bold>3</bold></td><td align="center"><bold>4</bold></td><td align="center"><bold>5</bold></td><td align="center"><bold>6</bold></td><td align="center"><bold>7</bold></td><td align="center"><bold>8</bold></td></tr></thead><tbody><tr><td align="left"><bold>Drug regimen</bold></td><td align="center">ETB</td><td></td><td align="center">ETB</td><td align="center">ETB</td><td></td><td align="center">ETB</td><td></td><td></td></tr><tr><td></td><td></td><td align="center">RIF</td><td></td><td></td><td align="center">RIF</td><td></td><td align="center">RIF</td><td align="center">RIF</td></tr><tr><td></td><td align="center">ETN</td><td></td><td align="center">ETN</td><td align="center">ETN</td><td></td><td align="center">ETN</td><td></td><td></td></tr><tr><td></td><td></td><td align="center">ETB</td><td></td><td></td><td align="center">ETB</td><td></td><td align="center">ETB</td><td align="center">ETB</td></tr><tr><td></td><td align="center">PRZ</td><td></td><td align="center">PRZ</td><td align="center">PRZ</td><td></td><td align="center">PRZ</td><td></td><td></td></tr><tr><td></td><td></td><td align="center">PRZ</td><td></td><td></td><td align="center">PRZ</td><td></td><td align="center">PRZ</td><td align="center">PRZ</td></tr><tr><td></td><td align="center">CPF</td><td></td><td align="center">CPF</td><td align="center">CPF</td><td></td><td align="center">CPF</td><td></td><td></td></tr><tr><td></td><td></td><td align="center">KAN</td><td></td><td></td><td align="center">KAN</td><td></td><td align="center">KAN</td><td align="center">KAN</td></tr><tr><td></td><td align="center">KAN</td><td></td><td align="center">KAN</td><td align="center">AMK</td><td></td><td align="center">KAN</td><td></td><td></td></tr><tr><td align="left"><bold>Gain BMI (Kg/m<sup>2</sup>)</bold></td><td align="center">1.8</td><td align="center">0.4</td><td align="center">0.4</td><td align="center">0.4</td><td align="center">0.3</td><td align="center">2.2</td><td align="center">1.8</td><td align="center">- 2.1<sup>!</sup></td></tr><tr><td align="left"><bold>Sputum smear status</bold></td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td></tr><tr><td align="left"><bold>Sputum culture status</bold></td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td><td align="center">Negative</td></tr><tr><td align="left"><bold>Conversion time</bold></td><td align="center">2 mo.</td><td align="center">3 mo.</td><td align="center">3 mo.</td><td align="center">1 mo.</td><td align="center">3 mo.</td><td align="center">2 mo.</td><td align="center">2 mo.</td><td align="center">3 mo.</td></tr><tr><td align="left"><bold>Thorax X-ray</bold></td><td align="center">Residual fibrosis</td><td align="center">Reabsorption and residual fibrosis</td><td align="center">Residual bilateral fibrosis.</td><td align="center">Lesions resolution</td><td align="center">Residual fibrosis</td><td align="center">Lesions size reduction</td><td align="center">Residual fibrosis</td><td align="center">Lesions size reduction</td></tr><tr><td align="left"><bold>GSR (mm/h)</bold></td><td align="center">5</td><td align="center">48</td><td align="center">26</td><td align="center">40</td><td align="center">42</td><td align="center">20</td><td align="center">23</td><td align="center">77</td></tr></tbody></table><table-wrap-foot><p>Legend: see Table 1</p><p>! Lost body weight</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Bacteriological evolution of DR-TB historical controls at "Ben&#x000e9;fico Jur&#x000ed;dico" Hospital (1994&#x02013;1999) under specific chemotherapy. These patients had failed to respond to the standard DOTS regime and were then further treated with chemotherapy according to the sensitivity of their strains.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="4"><bold>Sputum acid-fast-bacillus smear status</bold></td><td align="center" colspan="4"><bold>Sputum culture status</bold></td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="center" colspan="2"><bold>Positive</bold></td><td align="center" colspan="2"><bold>Negative</bold></td><td align="center" colspan="2"><bold>Positive</bold></td><td align="center" colspan="2"><bold>Negative</bold></td></tr></thead><tbody><tr><td align="center"><bold>Trimester</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>%</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>%</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>%</bold></td><td align="center"><bold>N</bold></td><td align="center"><bold>%</bold></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="center"><bold>1</bold></td><td align="center">17</td><td align="center">89.5</td><td align="center">2</td><td align="center">10.5</td><td align="center">19</td><td align="center">100</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="center"><bold>2</bold></td><td align="center">5</td><td align="center">26.3</td><td align="center">10</td><td align="center">52.6</td><td align="center">8</td><td align="center">42.1</td><td align="center">7</td><td align="center">36.8</td></tr><tr><td align="center"><bold>3</bold></td><td align="center">2</td><td align="center">10.5</td><td align="center">9</td><td align="center">47.4</td><td align="center">2</td><td align="center">10.5</td><td align="center">9</td><td align="center">47.4</td></tr><tr><td align="center"><bold>4</bold></td><td align="center">2</td><td align="center">10.5</td><td align="center">9</td><td align="center">47.4</td><td align="center">2</td><td align="center">10.5</td><td align="center">9</td><td align="center">47.4</td></tr></tbody></table><table-wrap-foot><p>Five patients died and other three interrupted the chemotherapy before concluding it. Percents are calculated considering initial DR-TB population (19 patients)</p></table-wrap-foot></table-wrap></sec></back></article>



